Skip to main content
SpringerLink
Log in

Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia

  • Obstetrics and Gynecology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objective

To investigate the relationship between immunohistochemical characteristics and recurrence after complete remission (CR) with fertility preservation treatment in patients with endometrial cancer (EC) and endometrial atypical hyperplasia (AH).

Methods

The clinical data and immunohistochemical results of 53 patients with EC and 68 patients with AH admitted to Peking University People’s Hospital from January 2010 to January 2021 were retrospectively analyzed. Patients were divided into two groups according to whether recurrence after complete remission (CR): group 1: recurrence after CR; group 2: no recurrence after CR, for statistical analysis.

Results

(1) The expression rate of ER in group 1 was lower than that in group 2, (P < 0.05). The expression rate of Ki-67 in group 1 was significantly higher than that in group 2, (P < 0.01). The expression rates of PR, P16, P53, and PTEN were not significantly different between the two groups (P > 0.05); (2) combination index ER/ Ki-67 row ROC curve analysis, there was a significant difference (P < 0.01), the best cut-off value was 3.55, sensitivity 0.730, specificity 1.000, Youden index 0.730. The 3-year RFS of high rate patients was 100%, and that of low rate patients was 42.3%, P < 0.01.

Conclusions

The expression rate of Ki-67 is of great significance in predicting the recurrence of EC after fertility preservation therapy. The best cut-off value of combination index ER/ Ki-67 (3.55) was better than a single immunohistochemical marker in predicting recurrence of EC after fertility preservation treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zaino RJ, Kauderer J, Trimble CL et al (2006) Reproducibility of the diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 106(4):804–811

    Article  PubMed  Google Scholar 

  2. Corzo C, Barrientos Santillan N, Westin SN et al (2018) Updates on conservative management of endometrial cancer. J Minim Invasive Gynecol 25(2):308–313

    Article  PubMed  Google Scholar 

  3. Koskas M, Uzan J, Luton D et al (2014) Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 101(3):785–794

    Article  PubMed  Google Scholar 

  4. Zhou H, Cao D, Yang J et al (2017) Gonadotropin-releasing hormone agonist combined with a levonorgestrel-releasing intrauterine system or letrozole for fertility-preserving treatment of endometrial carcinoma and complex atypical hyperplasia in young women. Int J Gynecol Cancer 27(6):1178–1182

    Article  PubMed  Google Scholar 

  5. Pronin SM, Novikova OV, Andreeva JY et al (2015) Fertility-sparing treatment of early endometrial cancer and complex atypical hyperplasia in young women of childbearing potential. Int J Gynecol Cancer 25(6):1010–1014

    Article  PubMed  Google Scholar 

  6. Baek JS, Lee WH, Kang WD et al (2016) Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: is it effective? Obstet Gynecol Sci 59(1):24–31

    Article  PubMed  PubMed Central  Google Scholar 

  7. Sasada S, Yunokawa M, Takehara Y et al (2018) Baseline risk of recurrence in stage I-II endometrial carcinoma. J Gynecol Oncol 29(1):e9

    Article  PubMed  Google Scholar 

  8. Takahashi K, Yunokawa M, Sasada S et al (2019) A novel prediction score for predicting the baseline risk of recurrence of stage I-II endometrial carcinoma. J Gynecol Oncol 30(1):e8

    Article  PubMed  Google Scholar 

  9. Gottwald L, Pluta P, Piekarski J et al (2010) Long-term survival of endometrioid endometrial cancer patients. Arch Med Sci AMS 6(6):937–944

    Article  PubMed  Google Scholar 

  10. Bendifallah S, Ouldamer L, Lavoue V et al (2017) Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study group. Gynecol Oncol 144(1):107–112

    Article  PubMed  Google Scholar 

  11. Chen X, Luo X (2019) Fertility-preserving treatment for early stage endometrial cancer. Chin J Pract Gynecol Obstet 35(6):618–623

    CAS  Google Scholar 

  12. Jeon YT, Park IA, Kim YB et al (2006) Steroid receptor expressions in endometrial cancer: clinical significance and epidemiological implication. Cancer Lett 239(2):198–204

    Article  CAS  PubMed  Google Scholar 

  13. Gülseren V, Kocaer M, Özdemir İA et al (2020) Do estrogen, progesterone, P53, and Ki67 receptor ratios determined from curettage materials in endometrioid-type endometrial carcinoma predict lymph node metastasis? Curr Probl Cancer 44(1):100498

    Article  PubMed  Google Scholar 

  14. Temraz S, Shamseddine A, Mukherji D et al (2019) Ki67 and P53 in relation to disease progression in metastatic pancreatic cancer: a single institution analysis. Pathol Oncol Res POR 25(3):1059–1066

    Article  PubMed  Google Scholar 

  15. Li J, Liu ZY, Yu HB et al (2020) Clinicopathological significance of Ki67 expression in colorectal cancer: a protocol of systematic review and meta-analysis. Medicine 99(20):e20136

    Article  PubMed  PubMed Central  Google Scholar 

  16. Jacobsen F, Kohsar J, Gebauer F et al (2020) Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget 11(12):1007–1016

    Article  PubMed  PubMed Central  Google Scholar 

  17. Gao X, Zhao L, Shen D et al (2014) Study of molecular markers in patients with endometrial carcinoma and its prognosis on the effectiveness. Chin J Clin Obstet Gynecol 15(6):519–522

    Google Scholar 

  18. Feng M, Hong Bu, Wang W et al (2019) Progress in molecular classification of endometrial cancer and its clinical significance. Chin J Pathol 48(12):997–1000

    CAS  Google Scholar 

  19. Jiang P, Jia M, Hu J et al (2020) Prognostic value of Ki67 in patients with stage 1–2 endometrial cancer: validation of the cut-off value of Ki67 as a predictive factor. OncoTargets Ther 13:10841–10850

    Article  Google Scholar 

  20. Jia M, Jiang P, Huang Z et al (2020) The combined ratio of estrogen, progesterone, Ki-67, and P53 to predict the recurrence of endometrial cancer. J Surg Oncol 122(8):1808–1814

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

National Key Technology R&D Program of China (Nos. 2019YFC1005200 and 2019YFC1005201); National Natural Science Foundation of China (81972426).

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Peking University People’s Hospital, Beijing, 100044, China

    Liwei Li, Zerui Xiao, Yiqin Wang, Yijiao He, Zhiqi Wang & Jianliu Wang

  2. Department of Pathology, Peking University People’s Hospital, Beijing, 100044, China

    Danhua Shen

Authors
  1. Liwei Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zerui Xiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yiqin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yijiao He
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zhiqi Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Danhua Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jianliu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

ZW, JW contributed to the conception of the study; LL performed the data analyses and wrote the manuscript; YW, YH contributed significantly to analysis and manuscript preparation; ZX, DS helped perform the analysis with constructive discussions.

Corresponding author

Correspondence to Zhiqi Wang.

Ethics declarations

Conflict of interest

The authors declared no potential conflict of interest with respect to the research, authorship and/or publication of this article.

Ethical approval

This study was approved by Institutional Review Board of Peking university people’ hospital.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, L., Xiao, Z., Wang, Y. et al. Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia. Arch Gynecol Obstet 307, 2025–2031 (2023). https://doi.org/10.1007/s00404-022-06398-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-022-06398-3

Keywords

Search

Navigation